Journal of Inflammation Research (Jan 2020)
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
Abstract
Vidhatha Reddy, 1 Eric J Yang, 2 Bridget Myers, 1 Wilson Liao 1 1San Francisco Department of Dermatology, University of California, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San Francisco, CA 94118, USATel +1 661-340-3418Email [email protected]: Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.Keywords: risankizumab, plaque psoriasis, IL-23 inhibitor, biologics, safety, efficacy
